Dr. Jeffrey Jones on Long-Term Outcomes With Ibrutinib in CLL

Jeffrey Jones, MD, MPH
Published: Monday, Aug 15, 2016


Jeffrey Jones, MD, MPH, assistant professor of Internal Medicine, Division of Hematology, Department of Internal Medicine, Ohio State University Wexner Medical Center, discusses the long-term outcomes associated with ibrutinib (Imbruvica) for the treatment of patients with chronic lymphocytic leukemia (CLL).

For chemoimmunotherapy, researchers can estimate the long-term responses patients may or may not have. However, the same cannot be said for ibrutinib, as it is a newer agent in the field, Jones explains. For younger patients receiving ibrutinib, it is important to consider long-term toxicities that have yet to emerge, as well as treatment compliance.

This varies for patients depending on their age, as older patients may need to consider whether they would rather receive ibrutinib for an unprecedented amount of time versus 6 months of chemoimmunotherapy.

Jeffrey Jones, MD, MPH, assistant professor of Internal Medicine, Division of Hematology, Department of Internal Medicine, Ohio State University Wexner Medical Center, discusses the long-term outcomes associated with ibrutinib (Imbruvica) for the treatment of patients with chronic lymphocytic leukemia (CLL).

For chemoimmunotherapy, researchers can estimate the long-term responses patients may or may not have. However, the same cannot be said for ibrutinib, as it is a newer agent in the field, Jones explains. For younger patients receiving ibrutinib, it is important to consider long-term toxicities that have yet to emerge, as well as treatment compliance.

This varies for patients depending on their age, as older patients may need to consider whether they would rather receive ibrutinib for an unprecedented amount of time versus 6 months of chemoimmunotherapy.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: The Next Generation in Renal Cell Carcinoma Treatment: An Oncology Nursing Essentials WorkshopJul 31, 20181.5
Publication Bottom Border
Border Publication
x